Kraig Biocraft Laboratories, Inc., the biotech company known for its pioneering work in genetic engineering for the production of spider silk and other polymers, is constantly breaking new ground in the field of genetics. As such, it is not surprising that they have assembled a remarkable team of scientific advisors to play a major role in everything they do.

• Malcolm J. Fraser, Jr., Ph.D, specializes in molecular genetics, and currently heads the Fraser Laboratory at the University of Notre Dame. During his post-doctoral work at Texas A&M, Dr. Fraser was part of the team which developed the genetic expression system for producing organic molecules, including pharmaceuticals, on an industrial scale. He is the co-inventor of the “piggyBac” gene splicing technology, and the named inventor for various patents involving its improvement.

He was recently selected as a fellow of the American Association for the Advancement

Emerging biotech company, Kraig Biocraft Laboratories, Inc. was founded by the inventor of the company’s technology, current chief executive officer, Kim Thompson. The company is a fully reporting organization and trades on the over-the-counter market under the stock symbol KBLB. As of last report, there are about 501 million common shares outstanding, with approximately 64% held by the chief executive officer.

Kraig Biocraft Laboratories’ CEO serves as the overall coordinator for the company relative to business operations and ongoing research and development. Several prominent genetic scientists have significantly developed the companies’ technologies. Additionally, the laboratory staffs of these professors are also making significant contributions to the company’s efforts.

Kraig Biocraft Laboratories, Inc. has a developed intellectual portfolio relating to the harvesting of silk from genetically modified silkworms. The company brings together preeminent researchers in a collaborative effort to produce commercially significant quantities of

We have been covering Kraig Biocraft Laboratories since December of last year. Those who have read our articles understand why we are excited about this company’s prospects to develop a “super fiber” that can be sold into the technical textiles industry. This super fiber, spider silk, has truly remarkable properties and may have numerous commercial and consumer applications.

Currently Kraig Biocraft is in the research and development stage, but has been making excellent progress in the labs and is now capable of accomplishing five thousand genetic transfers in a single week using its newly designed DNA insertion packets. Additional lab personnel and a change in techniques has significantly boosted productivity and the company’s odds of success.

Artificial or transgenic production of spider silk will surely be viewed by the scientific community as a major breakthrough. Such a development would also likely yield significant coverage in the

Malcolm. J. Fraser, Jr. Ph.D. earned his Ph.D from Ohio State University and performed postdoctoral research at Penn State University and Texas A&M University. At the Texan University, he played a key role in developing the genetic expression system which is now a widely used methodology for producing organic molecules, including pharmaceuticals, on an industrial scale.

Randy Lewis, Ph.D received his B.S. in chemistry from the California Institute of Technology, and his M.S. in chemistry and Ph.D. in Biochemistry from the University of California, San Diego. Dr. Lewis, internationally renowned for his work on spider silk, is the named inventor of a number of patents relating to spider silk polymers. He currently heads the Lewis Laboratory within the Department of Molecular Biology at the University of Wyoming. The study of spider silk polymers and their underlying genetics is a major focus of Dr. Lewis’s research.

Donald